Le Lézard
Classified in: Health
Subjects: LAW, AVO

Court Ruling Against FDA's Graphic Cigarette Warnings is Wrong on the Law and Must Be Appealed


Statement of American Academy of Pediatrics, American Cancer Society, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, Campaign for Tobacco-Free Kids and Truth Initiative

WASHINGTON, Dec. 7, 2022 /PRNewswire/ -- Today's decision by a federal judge to block implementation of graphic cigarette warnings ordered by the Food and Drug Administration (FDA) is wrong on the law, inconsistent with decades of precedent and harms public health. We urge the Justice Department to appeal this decision, and we are confident that the FDA's warnings will ultimately be upheld by a higher court. Today's ruling was issued by U.S. District Judge J. Campbell Barker of the U.S. District Court for the Eastern District of Texas in a lawsuit filed by R.J. Reynolds and other tobacco interests.

Courts have long held that mandatory health warnings conveying truthful information about the risks of dangerous products do not violate the First Amendment. According to the court's ruling, however, the First Amendment permits only ineffective health warnings that do little to educate the public about the serious health risks of smoking.

The graphic cigarette warnings were mandated by a large, bipartisan majority of Congress as part of the 2009 Family Smoking Prevention and Tobacco Control Act. The graphic warnings developed by the FDA are a dramatic improvement over the current text-only warnings, which have become stale and unnoticed since they were last updated in 1984. They are supported by extensive scientific evidence showing that graphic warnings are most effective at increasing public understanding of the dire health consequences of smoking. And they would help the United States to catch up to the 120-plus countries that have already adopted this best-practice strategy to reduce tobacco use and save lives. Prior to 2009, when Congress passed the Tobacco Control Act, only 18 countries required graphic warnings, showing just how far behind the rest of the world the U.S. has fallen over the past 13 years.

The Tobacco Control Act required graphic warning labels covering the top half of the front and back of cigarette packs and 20% of cigarette advertising.

This lawsuit by R.J. Reynolds and a similar lawsuit filed by Philip Morris USA in the U.S. District Court for the District of Columbia show that these tobacco companies are being hypocritical when they claim they want to reduce the enormous harm caused by cigarettes. Far from helping to create a smoke-free future, these companies are doing everything they can to perpetuate cigarette sales and fight policies like graphic warnings and an end to menthol cigarette sales that would actually reduce cigarette use. That hypocrisy was also on full display recently in California where Reynolds and Philip Morris spent over $20 million in a failed referendum to overturn the state's law ending the sale of flavored tobacco products, including menthol cigarettes. California voters upheld the law by a 64% to 36% margin. But rather than accept the voters' verdict, Reynolds has already filed suit to block the California law and announced the introduction of a new line of cigarettes to circumvent the law and keep menthol smokers addicted.

Note To Editors: Late today, a federal judge in the U.S. District Court for the Eastern District of Texas issued an opinion blocking implementation of graphic warnings on cigarette packs and advertising ordered by the FDA in March 2020. Attached is a statement reacting to the opinion by the American Academy of Pediatrics, American Cancer Society, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, Campaign for Tobacco-Free Kids and Truth Initiative.

SOURCE Campaign for Tobacco-Free Kids


These press releases may also interest you

at 17:25
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

at 16:10
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...

at 16:10
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...



News published on and distributed by: